Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00112723 · OUTCOME

Pharmacodynamic Effects of Flavopiridol on Normal Peripheral Blood Mononuclear Cells (PBMCs).

Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma · Source last updated 2016-08-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Day 1

What was measured

The correlation of the pharmacodynamic effects of flavopiridol on normal peripheral blood mononuclear cells (PBMCs)

Analysis population: Data not available due to studies were not conducted by collaborating laboratory Investigator

Groups in this outcome

Dose Level 1 (Flavopiridol 30 mg/m2 + 30 mg/m2)

Patients receive flavopiridol IV over 4½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Dose Level 2 (Flavopiridol 30 mg/m2 + 50 mg/m2)

Patients receive flavopiridol IV over 4½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Dose Level 3 (Flavopiridol 50 mg/m2 + 50 mg/m2)

Patients receive flavopiridol IV over 4½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Dose Level 1 (Flavopiridol 30 mg/m2 + 30 mg/m2)0
Dose Level 2 (Flavopiridol 30 mg/m2 + 50 mg/m2)0
Dose Level 3 (Flavopiridol 50 mg/m2 + 50 mg/m2)0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      0
    3. group Id
      OG002
      value
      0
    units
    Participants
description
The correlation of the pharmacodynamic effects of flavopiridol on normal peripheral blood mononuclear cells (PBMCs)
groups
  1. description
    Patients receive flavopiridol IV over 4½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Dose Level 1 (Flavopiridol 30 mg/m2 + 30 mg/m2)
  2. description
    Patients receive flavopiridol IV over 4½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
    id
    OG001
    title
    Dose Level 2 (Flavopiridol 30 mg/m2 + 50 mg/m2)
  3. description
    Patients receive flavopiridol IV over 4½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
    id
    OG002
    title
    Dose Level 3 (Flavopiridol 50 mg/m2 + 50 mg/m2)
population Description
Data not available due to studies were not conducted by collaborating laboratory Investigator
reporting Status
POSTED
time Frame
Day 1
title
Pharmacodynamic Effects of Flavopiridol on Normal Peripheral Blood Mononuclear Cells (PBMCs).
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice